The inclusion of experimental and clinical data in a single volume, together with an emphasis on recent and controversial issues, combine to make this treatise unique in its approach to acute myelogenous leukemia (AML). Investigators from diverse disciplines critically examine what is now understood about the pathogenesis of this disease and discuss new and emerging therapeutic approaches. Chapters cover subjects ranging from leukemia in atomic bomb survivors to RAS gene mutations in AML and the pharmacologically directed design of AML therapy.
